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numerous other benefits, for cases typi-
cally referred for Mohs surgery. More-
over, Mohs surgery has been shown to
be either cost comparable or slightly
more expensive than excision with per-
manent sections and immediate recon-
struction but less costly when frozen
sections, delayed reconstruction, or sur-
gical facilities are employed.
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TO THE EDITOR
There is no basis for the assertion by
Dr Rogers and his colleagues (2014)
that our conclusions were erroneous
or affected by the study design. We
meticulously studied every patient with
basal cell carcinoma or cutaneous
squamous cell carcinoma diagnosed
over a 2-year period at two busy
hospitals at our academic medical
center. We had excellent follow-up on
virtually all patients, and we analyzed
patients at the two hospitals separately
before pooling them. We could find no
evidence that long-term recurrence was
lower after Mohs surgery than after
excision, even with multiple analyses
that adjusted for differences in patient,
tumor, and care characteristics. We
conclude that any difference in
recurrence rates could be determined
only in a randomized controlled trial in
which similar patients with similar
tumors are randomized to receive one
treatment or another.
It is clear that for most nonmelanoma
skin cancers, there is insufficient evidence—
from our large prospective cohort study
and the European randomized controlled
trial in facial basal cell carcinomas
(Mosterd et al., 2008)—to guide choices
between therapies. What this means for
our specialty is that we have no data to
justify the dramatic increase in Mohs
surgery utilization in the USA over the
last decades given that Mohs surgery is not
the less expensive treatment (Wilson et al.,
2012). Because they are costly, rando-
mized controlled trials often are conduc-
ted after observational studies demonstrate
clinical equipoise in important, targeted
situations. This is precisely the situation in
which we find ourselves for many non-
melanoma skin cancers. The results of our
studies strongly support a focused rando-
mized controlled trial of surgical
treatments for nonmelanoma skin cancer,
and I urge Dr Rogers and colleagues, as
respected Mohs surgeons and leaders, to
join me in supporting this next scientific
approach to studying the comparative
efficacy of these treatments.
In my experience, arguments against
such a trial typically fall into three types.
First is the conviction that a trial is not
indicated and may be unethical because
the result would be obvious, since a
therapy that eliminates every visible
tumor cell and spares normal tissue will
of course be curative and therefore
superior. Such a belief is wrong in, for
example, prostate cancer (Wilt and
Ahmed, 2013), and the consistency of
our findings and those of the European
study for both clinical (Mosterd et al.,
2008) and patient-reported (Essers et al.,
2006; Chren et al., 2007) outcomes
demonstrates that it may be wrong for
basal cell carcinoma and cutaneous
squamous cell carcinoma. Second is
the perspective that since nonme-
lanoma skin cancer is typically
nonfatal, the care of these tumors is
too trivial to warrant further study. In
fact, of course, these tumors are a
burden for the public health; for
example, the Global Burden of DiseaseAccepted article preview online 12 November 2013; published online 21 November 2013
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Study determined that the disability-
adjusted life years from nonmelanoma
skin cancer are equal to those from
melanoma and bladder cancer (Global
Burden of Disease Study, 2013). Finally,
apparent pragmatists argue that the cost
of a definitive randomized controlled
trial would be too great. This perspec-
tive seems short-sighted for our specialty,
as the care of nonmelanoma skin cancer
is a key part of our practices (Rogers
et al., 2010; Connolly et al., 2012), the
cost to Medicare is an important health-
care expense (Housman et al., 2003)
and the potential misuse of health-care
resources is significant enough to engen-
der substantial scrutiny by regulators
(Elston, 2013).
We in Dermatology should be at the
forefront of calls to the National Insti-
tutes of Health and other agencies to
address scientifically the gap in evi-
dence to guide care for the most com-
mon malignancy. We need a definitive
randomized controlled trial to deter-
mine the superior surgical treatment for
important subgroups of nonmelanoma
skin cancers. Only with data can we
know that we have ‘‘properly selected
skin cancer treatments.’’
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TO THE EDITOR
Rogers et al. (2014) appear to have
taken umbrage at my commentary
(Stern, 2013). For properly selected non-
melanoma skin cancers (NMSCs),
Mohs surgery is an excellent and often
optimal option. For these tumors, the
time, overhead, and intensity required
may justify the current reimbursement.
However, for many primary NMSCs
treated with Mohs surgery, as currently
priced and practiced in the United
States, Mohs is not a good value pro-
position for those who pay for medical
care and provides little additional
benefit to patients (https://www.federa
lregister.gov/, accessed 23 September
2013 and Wilson et al., 2011).
Standard therapies of primary NMSCs
outside of the H-zone and scalp, admini-
stered by those with procedural training,
have slightly higher recurrence rates, are
less expensive, take less patient time,
and usually give comparable results.
Differences in patient populations are
highly unlikely to explain the excep-
tional variability (46 and 416 fold
among States) in the percent of all
NMSCs of the face, neck, scalp, and
other sites, respectively, treated with
Mohs (Donaldson and Coldiron (2012);
Stern (2013)). The proportion of NMSCs
treated with Mohs was generally higher
in the States with more Mohs surgeons
per capita, particularly for tumors not on
the head. There must be greater vari-
ability among individual dermatologic
surgeons in the proportion of NMSCs
they treat with Mohs, for which the
clinical benefits justify the higher cost.
The number of Mohs procedures
performed has grown as the number of
Mohs Surgeons has increased (Maxwell
et al., 2007; Rogers and Coldiron,
2012). Almost certainly, the economics
and supply of Mohs surgery rather than
medical indications are the strongest
drivers of increased utilization. From
1992 to 2002, utilization rates of
Mohs for Medicare beneficiaries tripled
(Maxwell et al., 2007). Extrapolation
from these and 2009 data indicate a
rate of two Mohs surgeries per oneAccepted article preview online 24 October 2013; published online 21 November 2013
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